Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors
NCT05410743
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
SSTR2-positive Tumors
Interventions
DRUG:
177Lu-LNC1010 1
DRUG:
177Lu-LNC1010 2
DRUG:
177Lu-LNC1010 3
DRUG:
177Lu-LNC1010 4
Sponsor
The First Affiliated Hospital of Xiamen University